Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 11/20 | 0.44 |
| ▸ | SCN1A | P35498 | 6/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464949 | 1.00 | XPO1 (0.44) | XPO1SCN1ASCN8ARXFP1HSD11B1 | |
| SCHEMBL24360899 | 0.80 | HSD11B1 (0.39) | SCN1ASCN8AHSD11B1SCN5ASLC40A1 | |
| SCHEMBL29464874 | 0.78 | SCN1A (0.38) | SCN1ASCN8AHSD11B1SCN5ASLC40A1 | |
| SCHEMBL22117204 | 0.78 | SLC40A1 (0.41) | SCN1ASCN8AHSD11B1SCN5ASLC40A1 | |
| SCHEMBL24360868 | 0.78 | SCN1A (0.39) | SCN1ASCN8AHSD11B1SCN5ASLC40A1 | |
| SCHEMBL19927705 | 0.78 | SCN1A (0.38) | SCN1ASCN8AHSD11B1SCN5ASLC40A1 | |
| SCHEMBL22323258 | 0.77 | SCN1A (0.38) | SCN1ASCN8ARXFP1HSD11B1SCN5A | |
| SCHEMBL19925692 | 0.77 | SCN1A (0.38) | SCN1ASCN8AHSD11B1SCN5A | |
| SCHEMBL29464850 | 0.77 | SCN1A (0.38) | SCN1ASCN8AHSD11B1SCN5A | |
| SCHEMBL22323203 | 0.76 | SLC40A1 (0.40) | SCN1ASCN8ASCN5ASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | XPO1 1735/4885SCN1A 32/4885SCN8A 450/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | XPO1 1735/4885SCN1A 32/4885SCN8A 450/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | XPO1 1735/4885SCN1A 32/4885SCN8A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.